Published by Coherent Market Insights
Posted on September 29, 2021
6 min readLast updated: February 1, 2026
The Chagas Disease Treatment Market is set to grow at a 7.3% CAGR from 2021-2027, driven by rising prevalence and new drug approvals.
The Chagas Disease Treatment Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2021-2027). The research presents a complete assessment of the market and contains Future trend, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry validated market data.
Chagas Disease Treatment Market report presents the detail analysis of the parent market based on elite players, present, past and futuristic data which will serve as a profitable guide for all the industry competitors. Key players in the Chagas Disease Treatment market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All measurement shares, splits, and breakdowns have been resolute using secondary sources and verified primary sources. The Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure and all these together will help leading players understand scope of the Market, what characteristics it offers and how it will fulfill customer’s requirements.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/934
Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by Trypanosoma cruzi. The symptoms change over the course of the infection. Chagas disease can be treated with nifurtimox and benznidazole. Both medicines are nearly 100% effective in curing the disease. Benznidazole is approved by FDA for use in children 2–12 years of age. If left untreated, it can cause congestive heart failure. Chagas disease treatment focuses on taking medication that kills the parasite and on managing symptoms. Infection is lifelong, if untreated. Chagas disease (acute) occurs immediately after infection, and can last for few weeks/months. Hence, there is an increasing demand for safe and effective treatment, worldwide.
Key Market Drivers:
Increasing prevalence of chagas disease across the world is expected to augment the growth of the chagas disease treatment market during the forecast period. For instance, according to the World Health Organization (WHO), around 6 to 7 million people worldwide, mostly in Latin America, are estimated to be infected with T. cruzi, the parasite that causes Chagas disease.
Moreover, introduction of novel chagas disease treatment or increase in drug approvals to treat chagas disease is expected to accelerate the growth of the chagas disease treatment market. For instance, in August 2020, Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Lampit (nifurtimox) for use in pediatric patients (from birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of chagas disease.
COVID-19 Impact Analysis:
As the -19 pandemic advances, it increasingly impacts those who already bear a heavy burden of neglected tropical disease, such as Chagas disease. Chagas disease is of particular concern because of its potential to cause gastrointestinal, cardiac, and other complications which could increase susceptibility to COVID-19. Moreover, those who already have severe heart condition due to Chagas disease or a weakened immune system are at higher risk of COVID-19. This in turn is expected to increase the demand for chagas disease treatment, driving the growth of the chagas disease treatment market.
Key Takeaways:
The chagas disease treatment market is expected to exhibit a CAGR of XX % during the forecast period due to increasing focus towards new approaches to manage or tackle chagas disease. For instance, in December 2019, Unitaid launched a new projects that can help eliminate congenital infection of Chagas disease through better diagnosis and treatment, within the context of its work in maternal and child health. The new call reflects increased global attention and country commitment to fight Chagas disease.
Among regions, North America is expected to witness significant growth in the chagas disease treatment market due to increasing prevalence of chagas disease in this region. For instance, according to the Pan American Health Organization (PAHO), Chagas disease is endemic in 21 countries in the Americas, and affects around 6 million people. Moreover, it is estimated that around 70 million Americans live in areas where exposure and the risk of contracting this disease is high.
Latin America is expected to witness robust growth in the chagas disease treatment market due to increasing prevalence of chagas disease in this region. For instance, according to the Centers for Disease Control and Prevention (CDC), Chagas is common in parts of Mexico, Central America, and South America where an estimated 8 million people are infected.
What Chagas Disease Treatment Market report offers:
Major Players Analysed The Market
These Players Are: Nortec Quimica SA, Bayer AG, Laboratorio Elea Phoenix SA, Maprimed S.A., and Laboratório Farmacêutico de Pernambuco S/A.
Remarkable Attributes of Chagas Disease Treatment Market Report:
Buy This Research Study Report For Quick Access with flat US $ 2000 off@ https://www.coherentmarketinsights.com/promo/buynow/934
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
The post Chagas Disease Treatment Market Size Expected to Witness Growth at a CAGR of 7.3% for the Study Period 2021-2027 appeared first on Gatorledger.
The article discusses the growth of the Chagas Disease Treatment Market, projected to expand at a 7.3% CAGR from 2021 to 2027.
How does FDA approval impact the market? FDA approvals, like that of Lampit, boost market growth by introducing new treatment options.
What is the impact of COVID-19 on the market? COVID-19 increases demand for treatment due to heightened risk for Chagas patients.
Explore more articles in the Research Reports category
